Back
Xtrackers RREEF Global Natrl Res ETF Vs. Apellis Pharmaceuticals Industry Stock Comparison
Sell
40
NRES
Xtrackers RREEF Global Natrl Res ETF
Last Price:
26.56
Seasonality Move:
--
Sell
19
APLS
Apellis Pharmaceuticals
Last Price:
32.71
Seasonality Move:
18.8%
Sell
40
Xtrackers RREEF Global Natrl Res ETF (NRES)
is a Sell
Is Xtrackers RREEF Global Natrl Res ETF a Buy, Sell or Hold?
- The current Xtrackers RREEF Global Natrl Res ETF [NRES] share price is $26.56. The Score for NRES is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.
- NRES is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
19
Apellis Pharmaceuticals (APLS)
is a Sell
Is Apellis Pharmaceuticals a Buy, Sell or Hold?
- The current Apellis Pharmaceuticals [APLS] share price is $32.50. The Score for APLS is 19, which is 62% below its historic median score of 50, and infers higher risk than normal.
- APLS is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.
- This Score is currently showing an extreme reading that indicates risk could be especially high.
NRES Stock Price Chart
What is Xtrackers RREEF Global Natrl Res ETF's stock price today?
-
The Xtrackers RREEF Global Natrl Res ETF share price today is $26.56
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and NRES is experiencing selling pressure, which indicates risk of future bearish movement.
APLS Stock Price Chart
What is Apellis Pharmaceuticals's stock price today?
-
The Apellis Pharmaceuticals share price today is $32.50
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and APLS is experiencing slight selling pressure.
NRES Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.02 | Sell |
Relative Strength Index (14 RSI): | 52.82 | Buy |
Chaikin Money Flow: | -149 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (25.86 - 27.06) | Buy |
Bollinger Bands (100): | (26.15 - 27.73) | Sell |
APLS Technical Analysis
Chart Indicators | Level | Buy or Sell |
---|---|---|
MACD (12, 26): | -0.84 | Sell |
Relative Strength Index (14 RSI): | 33.6 | Sell |
Chaikin Money Flow: | -1084788 | - |
Bollinger Bands | Level | Buy or Sell |
---|---|---|
Bollinger Bands (25): | (36.37 - 40.01) | Sell |
Bollinger Bands (100): | (36.55 - 42.35) | Sell |
NRES Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 26.28 | Buy |
20-day SMA: | 26.38 | Buy |
50-day SMA: | 26.52 | Buy |
200-day SMA: | 0 | Buy |
8-day EMA: | 26.41 | Buy |
20-day EMA: | 26.34 | Buy |
50-day EMA: | 26.49 | Buy |
200-day EMA: | 4.1 | Buy |
APLS Moving Averages
Moving Averages | Level | Buy or Sell |
---|---|---|
8-day SMA: | 36.19 | Sell |
20-day SMA: | 38.04 | Sell |
50-day SMA: | 37.88 | Sell |
200-day SMA: | 50 | Sell |
8-day EMA: | 35.96 | Sell |
20-day EMA: | 37.21 | Sell |
50-day EMA: | 38.25 | Sell |
200-day EMA: | 45.7 | Sell |
Xtrackers RREEF Global Natrl Res ETF Earnings Growth & NRES Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Apellis Pharmaceuticals Earnings Growth & APLS Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.74 per share, an increase next quarter of $0.23 per share, an increase this year of $3.28 per share, and an increase next year of $1.34 per share.
Xtrackers RREEF Global Natrl Res ETF Technical Analysis
Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|
Sep | ||||||||||
09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | 19 | 20 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |
Apellis Pharmaceuticals Technical Analysis
Sep 9 | Sep 10 | Sep 11 | Sep 12 | Sep 13 | Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | |
---|---|---|---|---|---|---|---|---|---|---|
Sep | ||||||||||
09 | 10 | 11 | 12 | 13 | 16 | 17 | 18 | 19 | 20 | |
Technical Analysis: Buy or Sell? | ||||||||||
8-day SMA: | ||||||||||
20-day SMA: | ||||||||||
50-day SMA: | ||||||||||
200-day SMA: | ||||||||||
8-day EMA: | ||||||||||
20-day EMA: | ||||||||||
50-day EMA: | ||||||||||
200-day EMA: | ||||||||||
MACD (12, 26): | ||||||||||
Relative Strength Index (14 RSI): | ||||||||||
Bollinger Bands (25): | ||||||||||
Bollinger Bands (100): |